FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed ...

FDA updates CAR T-cell therapy labels for liso-cel and ide-cel, easing monitoring requirements and expanding access for ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Panelists discuss how to approach a 67-year-old man with advanced polycythemia vera who is resistant to hydroxyurea, ...

Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line ...

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

GLP-1 receptor agonists show promise in reducing cancer risk and enhancing early detection, highlighting the need for further research in oncology.

Panelists discuss how diagnosis and staging of anal cancer involves digital rectal examination, high-resolution anoscopy with biopsy, p16 testing, and pelvic MRI for accurate staging, while ...

Panelists discuss how anal cancer epidemiology shows increasing incidence in both sexes with HPV infection as the primary risk factor, affecting predominantly women with a median age of 60, while ...

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with ...

Detalimogene voraplasmid gains FDA RMAT designation, showcasing a 71% response rate in treating high-risk, BCG-unresponsive ...